Market Overview
The global breast cancer liquid biopsy market size was valued at USD 1,209.01 million in 2024, exhibiting a CAGR of 8.5% during the forecast period.
Liquid biopsy for breast cancer — primarily tests analyzing circulating tumor DNA, circulating tumor cells (CTCs), methylation patterns, and other blood-based biomarkers — offers clinicians a faster, less invasive route to genomic profiling, therapy selection, and disease monitoring compared with repeat tissue biopsies. Recent regulatory milestones and growing payer recognition have broadened clinical adoption, particularly for advanced and metastatic breast cancer and companion-diagnostic applications in hormone receptor–positive and HER2-negative subtypes.
Market Scope —
- Test Types and Platforms — Next-generation sequencing (NGS)-based comprehensive genomic profiling (CGP), targeted PCR panels, CTC assays, and epigenetic assays (methylation) each address different clinical needs.
- Clinical Applications — Companion diagnostics for targeted therapies, detection of actionable mutations (e.g., PIK3CA, ESR1), minimal residual disease (MRD) monitoring, and therapy response surveillance.
- End Users and Channels — Oncology clinics, hospital laboratories, and centralized reference laboratories; partnerships between diagnostics developers and pharmaceutical companies are expanding access in clinical trials and routine care.
- Regulatory & Reimbursement Environment — FDA approvals and guideline endorsements for specific companion diagnostic uses, along with growing commercial and Medicare coverage, are reducing barriers to clinician uptake.
Key Market Growth Drivers
- Regulatory Validation of Liquid Biopsy Assays — FDA authorizations for liquid biopsy tests as companion diagnostics have strengthened clinician trust and enabled therapy matching in breast cancer.
- Shift Toward Precision Oncology — Rising availability of targeted therapies for molecularly defined breast cancer subgroups increases the clinical value of blood-based genomic profiling.
- Need for Minimally Invasive Monitoring — Liquid biopsy enables serial sampling for MRD and resistance monitoring without repeat tissue procedures.
- Technology Improvements and Cost Efficiencies — Advances in NGS, bioinformatics, and assay sensitivity are widening detectable mutation panels and reducing per-test turnaround time.
Market Challenges
- Analytical Sensitivity for Early-Stage Disease — Detecting very low tumor fractions remains technically challenging.
- Heterogeneity of Test Offerings — Differences in gene panels, reporting formats, and clinical claims complicate clinician selection and interpretation.
- Reimbursement Variability Across Regions — Broader reimbursement for surveillance and MRD remains uneven.
- Clinical Validation Requirements — Widespread adoption for new indications depends on large prospective studies and guideline updates.
Market Opportunities —
- Companion Diagnostic Expansion — New targeted agents and companion diagnostics provide opportunities to capture therapy-selection pathways.
- MRD and Recurrence Monitoring — Validated MRD assays could transform postoperative management.
- Integration with Clinical Trials and Real-World Evidence Programs — Collaborations with pharma can strengthen market position.
- Geographic Expansion and Payer Engagement — Evidence generation and local partnerships can accelerate adoption in APAC and Latin America.
Browse Full Insights:
https://www.polarismarketresearch.com/industry-analysis/breast-cancer-liquid-biopsy-market
Regional Analysis
- North America — Largest market due to clinical research activity, early reimbursement, and the presence of key diagnostics companies.
- Europe — Adoption is growing in specialized oncology centers; reimbursement varies by country but major markets are increasingly supportive.
- Asia-Pacific — Fastest potential growth region due to rising breast cancer incidence and expanding oncology infrastructure.
- Latin America & Middle East & Africa — Nascent markets with selective uptake; opportunities rely on affordability and public-private initiatives.
Key Companies
- Biocept, Inc.
- Epic Sciences, Inc.
- F. Hoffmann - La Roche Ltd.
- Fluxion Biosciences, Inc.
- Myriad Genetics, Inc.
- NeoGenomics Laboratories
- QIAGEN
- Sysmex Corporation
- The Menarini Group
- Thermo Fisher Scientific, Inc.
Conclusion
The Breast Cancer Liquid Biopsy market is poised for growth, driven by regulatory approvals, advancing assay technology, and the rising availability of targeted therapies. While challenges exist in sensitivity, standardization, and reimbursement, the market presents clear opportunities in companion diagnostics, MRD monitoring, clinical trial partnerships, and geographic expansion. Stakeholders are advised to monitor regulatory updates, payer coverage, and prospective clinical trials to capture the expanding market potential.
More Trending Latest Reports By Polaris Market Research:
Rising Consumption of Natural Resources to Drive Growth
Automotive Catalytic Converter Market
Gluten-Free Breakfast Cereals Market: A Nutritious Bowlful for Healthy Living
Elevators and Escalators Market
